BAJAJ

Ref: BHL/ STEX 21/ 2026-27
Date: July 20, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 **Scrip Code: 539872**	**National Stock Exchange of India Limited** 5th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 **Symbol: BAJAJHCARE**

Sub: Press Release for the quarter ended June 30, 2026

Dear Sir/Madam,

Please find enclosed the Press Release on the financial results of the Company for the quarter ended June 30, 2026.

Kindly take the same on record.

Thanking you.

Yours faithfully,

For and on behalf of Bajaj Healthcare Limited

MONICA TANWAR
Digitally signed by MONICA TANWAR
Date: 2026.07.20 20:45:37 +05'30'

Monica Tanwar
Company Secretary & Compliance Officer

Encl: As above

BAJAJ HEALTHCARE LTD
Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.
• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com
CIN No.: L99999MH1993PLC072892

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park,
Road No 23, Wagle Industrial Estate, Thane – 400 604
Website: www.bajajhealth.com
Email: investors@bajajhealth.com
CIN: L99999MH1993PLC072892

INVESTOR RELEASE

Bajaj Healthcare reports Q1 FY27 results

Revenue Up 11.3% YoY; EBITDA Up 16.4% and PAT Up 15.8% YoY

Mumbai, 20th July 2026: Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its unaudited financial results for the quarter ended 30th June 2026.

Highlights of Q1 FY27 Results

- Revenue from operations at Rs. 165.6 Crore, up **11.3% YoY** and 8.2% sequentially
- Gross profit at Rs. 80.4 Crore, up **16.2% YoY**; gross margin expanded to 48.3% from 46.2% in Q1 FY26
- EBITDA at Rs. 29.6 Crore, up **16.4% YoY**; EBITDA margin improved to 17.8% from 17.1% in Q1 FY26
- Profit after tax at Rs. 13.7 Crore, up **15.8% YoY**; PAT margin at 8.3%

Business Segment Performance

API — Domestic

Domestic API sales for the quarter were Rs. 92.3 Crore, up ~27% YoY from Rs. 72.6 Crore in Q1 FY26. The performance was driven by strong volume growth across key products.

API — Exports

API export sales were Rs. 50.1 Crore for the quarter, as compared to Rs. 52.2 Crore in Q1 FY26 despite temporary disruptions arising from the geopolitical situation in West Asia

Formulations

Formulations revenue was Rs. 23.3 Crore for the quarter, compared to Rs. 24.1 Crore in Q1 FY26, reflecting a temporary moderation during the period. The Company expects performance to normalize as FY27 progresses.

Quarterly Business Updates

- Bajaj Healthcare became the first company in India to secure SEC recommendation for the manufacture and marketing of Cenobamate Tablets, a key milestone towards the commercialization of this next-generation anti-seizure medication designed for the treatment of partial-onset seizures in adults.

- During the quarter, the Company filed two CEP applications, taking the cumulative CEP filings to twelve. Of these, eight CEPs have been approved, while four remain under review, further strengthening the Company's presence in the regulated European Union (EU) and United Kingdom (UK) markets.

Management Commentary

Commenting on the Results, Mr. Anil Jain – Managing Director said,

"We have commenced FY27 on a positive note, delivering healthy growth across key financial parameters. In Q1 FY27, revenue from operations grew 11.3% YoY, while improved product mix contributed to gross margin expansion to 48.3% from 46.2% in Q1 FY26. EBITDA increased 16.4% YoY, with EBITDA margin improving to 17.8%, reflecting the strength of our operational capabilities and disciplined execution. Profit after tax also recorded healthy growth of 15.8 % YoY.

Our API division delivered a strong performance during the quarter, recording 14.0% YoY growth and 13.5% sequential growth, driven by healthy demand across the business. While the formulations segment witnessed a marginal decline during the quarter, we expect the business mix to gradually normalize as FY27 progresses and market conditions improve.

We continue to strengthen the foundations for our next phase of growth. Our expanded state-of-the-art R&D Centre at Savli has now become operational, significantly enhancing our product development and process innovation capabilities. We are also progressing well towards the commercialization of Cenobamate Tablets following the regulatory milestone achieved during the quarter, reinforcing our commitment to building a differentiated specialty portfolio.

With a strong foundation and clear priorities, we remain committed to delivering sustainable growth and enhancing long-term value for all our shareholders."

Financial Snapshot- Q1 FY27

(Rs. Mn)

Particulars	Q1 FY27	Q1 FY26	Y-o-Y	Q4 FY26	Q-o-Q	FY26
API — Domestic	**922.6**	726.0	27.1%	868.5	6.2%	3,195.7
API — Exports	**500.6**	521.9	(4.1%)	385.4	29.9%	1,881.4
Formulations	**233.1**	240.5	(3.1%)	276.7	(15.8%)	1,033.2
Revenue from Operations	**1656.3**	1,488.4	11.3%	1530.6	8.2%	6,110.3
Gross Profit	**803.5**	691.3	16.2%	745.0	7.8%	3,017.7
Gross Margin (%)	**48.3%**	46.2%		47.8%		48.8%
EBITDA	**295.6**	253.9	16.4%	256.3	15.3%	1,119.5
EBITDA Margin (%)	**17.8%**	17.0%		16.7%		18.3%
PAT*	**137.0**	118.3	15.8%	104.0	31.8%	490.1
PAT Margin	**8.3%**	8.0%		6.8%		8.0%

** PAT is before exceptional items*

Earnings Call

The Company will host an earnings call at on 21st July, 2026, at 4:00 PM IST, where senior management will discuss the Company's performance and answer questions from participants. This call will be accessible through an audio dial-in and a webcast.

Audio Conference	Universal Dial In: +91 22 6280 1550 / +91 22 7115 8378 International Toll Free: Hong Kong : 800964448, UK : 08081011573, Singapore : 8001012045, USA : 18667462133
Pre-registration	Click Here
Webcast	Details will be provided through the Company's website, www.bajajhealth.com

To participate in the audio call, please dial the numbers provided five to ten minutes ahead of the scheduled start time. A transcript of the event will be made available on the Company's website following the call.

Disclaimer

This presentation contains forward-looking statements based on current expectations, assumptions, and estimates. Actual results may differ materially due to various risks and uncertainties. The Company undertakes no obligation to update or revise these statements, except as required under applicable laws and regulations.

About Bajaj Healthcare Limited

Bajaj Healthcare Limited is a leading manufacturer of APIs, Intermediates and Formulations. Established in 1993, it has built a strong reputation for delivering high quality pharmaceutical products, nutraceuticals across various therapies. The Company operates state-of-the-art manufacturing facilities that are designed to meet the requirements of both regulated and emerging markets. With a strong global presence, BHL serves customers across Europe, USA, Australia, Middle East, and South America.

Contacts

Company:

Mr. Rohan Parekh- CFO

Email: investors@bajajhealth.com

Investor Relations Advisors:

MUFG Intime India Private Limited

Ms. Prachi Ambre — prachi.ambre@in.mpms.mufg.com

Mr. Irfan Raeen — irfan.raeen@in.mpms.mufg.com